Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, preventing ...
Fact checked by Nick Blackmer The Food and Drug Administration (FDA) on Thursday approved Journavx (suzetrigine), a new non-opioid painkiller that promises to be nonaddictive. Journavx is approved to ...